Inclusion Criteria:

- Pathologically confirmed metastatic colorectal cancer

- Measurable disease according to RECIST V1.1

- Histological local review and analysis of KRAS

- Age ≥ 80 or ≥ 70 in combination with functional restrictions defined as limitation in
at least 2 of 8 IADL

- WHO performance status 0, 1 or 2

- Adequate bone marrow reserves: absolute neutrophil count ≥1.5 x 109 cells/L,
platelets ≥100 x 109 cells/L and uncorrected hemoglobin ≥10 g/dL (i.e., without blood
transfusion or use of erythropoietin)

- Adequate hepatic function: either AST or ALT ≤ 2.5x ULN (in presence of liver
metastases, either AST or ALT ≤ 5x ULN), total bilirubin <1.5xULN

- Adequate renal function: GFR > 60 ml/min as measured by Modification of Diet in Renal
Disease formula before receiving chemotherapy

- Normal 12 lead ECG without clinically significant abnormalities

- Sexually active male participants must use barrier methods of contraception.
Contraception period: from the treatment start, throughout the study, and until 30
days after the last protocol treatment administration.

- Written informed consent before randomization according to ICH/EU GCP, and local,
national and international regulations

Exclusion Criteria:

- Prior systemic chemotherapy for metastatic disease

- Previous exposure to EGFR or VEGF/VEGFR targeted therapy

- Patients may have received chemotherapy in the adjuvant or neoadjuvant setting (CRC).
The treatment-free interval should be 6 months or more from the end of (neo-)adjuvant
therapy

- Previous radiotherapy, either in the adjuvant setting or for the treatment of bone
metastases, is allowed provided that the measurable lesions are outside the radiation
fields

- Persistence of clinically relevant treatment-related toxicities from previous
chemotherapy and/or radiotherapy (adjuvant or neo-adjuvant setting)

- Treatment with other investigational drugs or treatment in another clinical trial
within the past four weeks before start of treatment or concomitantly with this trial

- Known alcohol or drug abuse

- Clinically significant cardiovascular disease (uncontrolled hypertension, New York
Heart Association class II-IV congestive heart failure, unstable angina pectoris
within the past 12 months, peripheral vascular disease ≥ grade 2, serious cardiac
arrhythmia requiring medication, myocardial infarction within the past 12 months,
other clinically significant cardiovascular disease)

- Evidence of uncontrolled medical comorbidities despite adequate treatment (according
to treating physician) like Diabetes mellitus, Chronic Obstructive Pulmonary Disease
(COPD), Serious infections requiring systemic antibiotic therapy (e.g. antimicrobial,
antifungal, antiviral)

- Patients who have suffered a cerebrovascular accident or transient ischemic attack
within the past 12 months

- History, within the past 5 years, of malignancies other than CRC (except: adequately
treated basal or squamous cell carcinoma of the skin, in situ carcinoma of the
cervix, resected incidental prostate cancer staged pT2 with Gleason Score <= 6 and
postoperative PSA < 0.5 ng/ml). Patients with any history of malignancies who are
disease-free for more than 5 years are eligible

- Psychological, familial, sociological, or geographical condition potentially
hampering compliance with the study protocol and followup schedule, those conditions
should be discussed with the patient before registration in the trial